Stock Ratings | Bank of America raised its price target for NBIS to $205; Guggenheim initiated coverage of CHRS with a buy rating and a price target of $12, indicating a potential upside of 515.38%.
Caribou Biosciences, Inc. CRBU | 0.00 | |
Artiva Biotherapeutics, Inc. ARTV | 0.00 | |
Coherus Oncology, Inc. CHRS | 0.00 | |
Tandem Diabetes Care, Inc. TNDM | 0.00 | |
InflaRx N.V. IFRX | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Caribou Biosciences ( Caribou Biosciences, Inc.(CRBU.US) ), with a price target raised from $9 to $11.
Cantor Fitzgerald: Maintaining an "overweight" rating on Artiva Biotherapeutics ( Artiva Biotherapeutics, Inc.(ARTV.US) ), while raising the price target from $10 to $40.
Wedbush: Maintaining Artiva Biotherapeutics ( Artiva Biotherapeutics, Inc.(ARTV.US) ) rating at "Outperform Market", while raising the price target from $23 to $40.
Guggenheim: Initial rating for Coherus BioSciences ( Coherus Oncology, Inc.(CHRS.US) ) at "buy", with a target price of $12.
Barclays: Maintaining an "overweight" rating on Tandem Diabetes Care ( Tandem Diabetes Care, Inc.(TNDM.US) ), while lowering its price target from $56 to $55.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Caribou Biosciences, Inc.(CRBU.US) | to lift | $11.0 | $2.03 | 441.87% | HC Wainwright & Co. |
| Artiva Biotherapeutics, Inc.(ARTV.US) | to lift | $40.0 | $10.6 | 277.36% | Cantor Fitzgerald |
| Artiva Biotherapeutics, Inc.(ARTV.US) | to lift | $40.0 | $10.6 | 277.36% | Wedbush |
| InflaRx N.V.(IFRX.US) | to lift | $8.0 | $2.5 | 220.0% | HC Wainwright & Co. |
| Avalo Therapeutics Inc(AVTX.US) | to lift | $60.0 | $20.25 | 196.3% | Piper Sandler |
| Coherus Oncology, Inc.(CHRS.US) | Initial classification | $12.0 | $1.95 | 515.38% | Guggenheim |
| Tandem Diabetes Care, Inc.(TNDM.US) | cut | $55.0 | $14.77 | 272.38% | Barclays |
| Vanda Pharmaceuticals Inc.(VNDA.US) | cut | $21.0 | $6.27 | 234.93% | HC Wainwright & Co. |
| CytomX Therapeutics, Inc.(CTMX.US) | cut | $11.0 | $3.86 | 184.97% | HC Wainwright & Co. |
| Niagen Bioscience, Inc.(NAGE.US) | cut | $11.0 | $3.98 | 176.38% | HC Wainwright & Co. |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Barclays: Maintaining CoreWeave's rating ( CoreWeave(CRWV.US) ) at "Market-Similar Weight", while raising the price target from $106 to $120.
Cantor Fitzgerald: Maintaining CoreWeave's rating ( CoreWeave(CRWV.US) ) at "Overweight", while raising the price target from $156 to $167.
JP Morgan: Maintaining IREN Limited(IREN.US) Limited's rating at "Underweight", while raising the price target from $39 to $46.
Macquarie: Maintaining IREN Limited's ( IREN Limited(IREN.US) ) rating at "Outperform Market", while raising the price target from $77 to $90.
B of A Securities: Maintaining the rating of Nebius Group ( NEBIUS(NBIS.US) ) at "Buy", while raising the price target from $175 to $205.
Cantor Fitzgerald: Maintaining Sterling Construction ( Sterling Infrastructure, Inc.(STRL.US) ) rating at "overweight", while raising the price target from $482 to $956.
First Coverage
RBC Capital: Initial rating for Arxis ( Arxis, Inc. Class A(ARXS.US) ) at "sector match", with a target price of $39.
Goldman Sachs: Initial rating for Madison Air Solutions ( Madison Air Solutions Corp. Class A(MAIR.US) ) at "neutral", with a target price of $44.
LUCID CAPITAL MARKETS: Initial rating for NextCure ( NextCure(NXTC.US) ) stock at "Buy", with a target price of $25.
JP Morgan: Initial rating for Oklo ( Oklo Inc. Class A(OKLO.US) ) stock at "neutral", with a price target of $83.
reduction
BTIG: Maintaining a "buy" rating on Carvana Carvana(CVNA.US) ) stock, while lowering the price target from $485 to $97.
Guggenheim: Maintaining a "buy" rating on DraftKings ( DraftKings(DKNG.US) ), while lowering the price target from $37 to $35.
Canaccord Genuity: Maintaining a "Hold" rating on Lyft ( Lyft(LYFT.US) ), while lowering the price target from $16 to $15.
Bernstein: Maintaining an "outperform" rating for ExxonMobil Exxon Mobil Corporation(XOM.US) ) stock, while lowering the price target from $195 to $182.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.